Joan S. McClure, MS, is Senior Vice President of Clinical Information and Publications for NCCN. Ms. McClure’s group develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), associated NCCN Guidelines for Patients, the NCCN Drugs & Biologics Compendium (NCCN Compendium), NCCN Chemotherapy Orders Templates (NCCN Templates), the NCCN Biomarkers Compendium, and JNCCN—Journal o...

Squamous cell carcinoma of the penis represents approximately 0.5% of all cancers among men in the United States and other developed countries. Although rare, it is associated with significant disfigurement, and only half of the patients survive beyond 5 years. Proper evaluation of both the primary lesion and lymph nodes is critical, because nodal involvement is the most important factor of sur...

Overview The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer: Noninvasive and Special Situations presented here are the work of the NCCN Breast Cancer panel members. Categories of evidence and consensus were assessed and are noted in the algorithms and text. Although not explicitly stated at every decision point of the guidelines, patient participation in prosp...

The NCCN Guidelines for Palliative Care provide interdisciplinary recommendations on palliative care for patients with cancer. The NCCN Guidelines are intended to provide guidance to the primary oncology team on the integration of palliative care into oncology. The NCCN Palliative Care Panel's recommendations seek to ensure that each patient experiences the best quality of life possible through...

Overview The NCCN Non-Melanoma Skin Cancer Panel has developed these guidelines outlining the treatment of dermatofibrosarcoma protuberans (DFSP) to supplement their other guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Basal Cell and Squamous Cell Skin Cancers and Merkel Cell Carcinoma; to view the most recent version of these guidelines, visit the NCCN Web site...

BACKGROUND To evaluate off-label and off-NCCN guidelines uses of antineoplastic drugs in a major Chinese hospital. METHODS Totally 1122 patients were selected from July to December 2011. Then, the off-label and off-NCCN guidelines uses of antineoplastic drugs were analyzed. RESULTS In 798 of 1122 patients (71.12%), drugs were used for off-label. In 317 of 1122 patients (28.25%), the drugs w...

mp2 calculations with cc-pvtz basis set were used to analyze intermolecular interactions in f3cx···yli···nccn and f3cx···nccn···liy triads (x = cl, br; y = cn, nc) which are connected via halogen and lithium bonds. those complexes with the role of liy as halogen acceptor and lithium donor show cooperativity with energy values ranging between -1.97 and -2.92 kj mol-1. those complexes with simult...

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence o...

These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. This manuscript is being updated to correspond with the newly updated algorithm. These guidelines are a statement of consensus of the authors regarding the...